

Please type a plus (+) inside this box +

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	6653-021-999	Total Pages
First Named Inventor or Application Identifier		
Yang Yunn-Bor		
Express Mail Label No. EV335857738US		

22890 10/7/02
4023 1021
106 1021
142463

APPLICATION ELEMENTS

See MPEP chapters 600 concerning utility patent application contents.

Commissioner for Patents
P.O. Box 1450
Mail Stop PATENT APPLICATION
Alexandria, VA 22313-1450

<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Applicant claims Small Entity status, see 37 C.F.R. § 1.27</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages 22] (preferred arrangement set forth below, MPEP 1503.01) - Descriptive title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R&D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description of the Invention (including drawings, if filed) - Claim(s) - Abstract of the Disclosure</p> <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets 4]</p> <p>5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Sheets 2] a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p>	<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</p> <p>8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Form (CRF) b. <input checked="" type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input checked="" type="checkbox"/> paper (copy from U.S. application no. 10/105,319 filed 03/26/02) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</p>
---	--

ACCOMPANYING APPLICATION PARTS

<p>9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney</p> <p>11. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>13. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(i). Applicant must attach form PTO/SB/35 or its equivalent</p> <p>17. <input type="checkbox"/> Other: Transmittal of Formal Drawings; Formal Drawings</p>
--

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP) | of prior application No.: 10/105,319 filed March 26, 2002

Prior application information: Examiner: Swope, Sheridan Group Art Unit: 1652

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number	20583 Insert Customer No.	or <input type="checkbox"/> Correspondence address below		
NAME				
ADDRESS				
CITY		STATE		ZIP CODE
COUNTRY		TELEPHONE		FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



16367 U.S. PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior application: Examiner Swope, Sheridan
 Art Unit 1652

Commissioner for Patents
 P.O. Box 1450
 Mail Stop PATENT APPLICATION
 Alexandria, VA 22313-1450

Sir:

This is a request for filing a continuation divisional application under 37 CFR § 1.53(b), of pending prior application no. 10/105,319 filed March 26, 2002.

of Yang Yunn-Bor, Wei Chia-Li, Hsu Jyh-Shing, and Tsai Ying-Chieh
 (inventor(s) currently of record in prior application)

for MUTATED PENICILLIN EXPANDASE AND PROCESS FOR PREPARING 7-ADCA USING THE SAME
 (title of invention)

1. The filing fee calculated below is based on the Preliminary Amendment submitted concurrently herewith:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	3	- 20	0	\$18.00 each	\$ 0.00
Independent	1	- 3	0	\$84.00 each	\$ 0.00
			Minimum Fee		\$ 770.00
			Multiple Dependency Fee		\$ 0.00
			If Applicable (\$280.00)		\$ 770.00
				Total	\$ 770.00
			Applicant qualifies for the 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern		\$ 385.00
				Total Filing Fee	\$ 385.00

2. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

3. Amend the specification by inserting before the first line the following sentence: This is a continuation, division, of application no. , filed .

4a. New formal drawings are enclosed.

4b. Informal drawings are enclosed.

5a. Priority of application no. filed on in is claimed under 35 U.S.C. § 119.


5b. The certified copy has been filed in prior application no. , filed .

PENNIE & EDMONDS LLP DOCKET NO 6653-021-999

6. The prior application is assigned of record to Synmax Biochemical Co., Ltd. recorded at Reel 01743, Frame 0562.
- 7a. A copy of the Declaration and Power of Attorney filed in the prior application no. 10/105,319 filed March 26, 2002 is enclosed.
- 7b. A Power of Attorney is enclosed.
8. This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§ 1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no. 10/105,319, filed March 26, 2002, be made a part of the present application as provided for by 37 C.F.R. § 1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. 10/105,319, filed March 26, 2002 is enclosed.
9. The undersigned states, under 37 C.F.R. § 1.821(f), that the content of the enclosed paper Sequence Listing from application no. 10/105,319, filed March 26, 2002, is the same as the content of the computer readable form submitted in application no. 10/105,319, filed March 26, 2002.
10. DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
11. Additional enclosures or instruction Preliminary Amendment; Transmittal of Formal Drawings; Information Disclosure Statement; and List of References AA-AK Cited By Applicants

Respectfully submitted,

Date November 21, 2003


Geraldine F. Baldwin
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711

31,232

(Reg. No.)

EXPRESS MAIL NO.: EV335857738US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Yang et al.	Confirmation No.:	To be assigned
Application No.:	To be assigned (Divisional of U.S. Patent Application No. 10/105,319)	Art Unit:	To be assigned
Filed:	September 25, 2003	Examiner:	To be assigned
For:	MUTATED PENICILLIN EXPANDASE AND PROCESS FOR PREPARING 7-ADCA USING THE SAME	Attorney Docket No.:	6653-021-999

TRANSMITTAL OF FORMAL DRAWINGS

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450


Sir:

Applicants submit herewith formal drawings in connection with the above-identified application. The formal drawings consist of four (4) sheets of drawings (corresponding to Figures 1-4).

Applicants respectfully request entry of the enclosed drawings in the file of the above-identified application.

Respectfully submitted,

Date: November 21, 2003


Geraldine F. Baldwin 31,232
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure